Kiel

• A randomized, multicenter, open-label trial comparing the effectiveness of Inclisiran to bempedoic acid on LDL cholesterol (LDL-C) lowering … Ended
  2024-511076-32-00 6 2024-06-21 Hypercholesterolemia
• An Open-label, Single-dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-77242113 in Adult Participants Ended
  2023-510161-97-00 3 2024-06-19 Renal Impairment
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended
  2022-501196-41-00 5 2024-05-29 Dermatitis atopic
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis Ended
  2023-506655-19-00 4 2024-05-16 Ulcerative Colitis (UC)
• A study to test how BI 456906 is taken up in the blood of people with and without kidney problems Ended
  2023-508557-13-00 3 2024-05-08 Renal impairment (mild, moderate and severe)
• A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject … Ended
  2023-505842-24-00 5 2024-05-07 Moderate to Severe Plaque Psoriasis
• A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants with Cirrhosis-ZEAL-UNLOCK Ended
  2023-506893-11-00 4 2024-04-19 Cirrhosis of the liver is a condition in which the liver is scarred an
• A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinet … Ended
  2023-505414-15-00 4 2024-04-10 Dermatitis, Atopic
• Regorafenib-pembrolizumab vs. TACE/TARE in intermediate-stage HCC beyond up-to-7. Ended
  2022-501969-42-00 5 2024-03-28 Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criter
• A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended
  2023-504678-39-00 4 2024-03-13 Heart Failure
• A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 … Ended
  2023-506092-10-00 4 2024-03-11 Stage III-IVA Resectable Locoregionall Advanced Head and Neck Squamous
• A prospective, randomized, double-blind placebo-controlled multicentre study with mannan-conjugated birch pollen allergoids administered sub … Ended
  2023-508013-16-00 5 2024-02-26 Birch pollen induced allergic rhinitis or rhinoconjunctivitis
• A Window-of-Opportunity study of hormone therapy in premenopausal women with ER-positive/HER2-negative early breast cancer. Ended
  2022-503013-32-00 4 2024-01-29 ER-positive/HER2-negative early breast cancer
• An open-label, single-dose, parallel-group study to evaluate the plasma pharmacokinetics of leniolisib in subjects with impaired hepatic fun … Ended
  2023-508519-22-00 3 2024-01-26 Activated Phosphoinositide 3-Kinase Delta Syndrome
• Hidradenitis Suppurativa Phase 3 Study of Izokibep Ended
  2022-503160-33-00 5 2023-12-15 Hidradenitis Suppurativa
• Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended
  2023-504673-20-00 4 2023-12-06 Ulcerative Colitis
• Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Ended
  2022-503062-72-00 4 2023-11-23 Chronic Spontaneous Urticaria
• Safety, tolerability, and efficacy of ACOU085 for prevention of hearing loss in testicular cancer patients receiving cisplatin Ended
  2023-503696-15-00 4 2023-11-10 sensorineural hearing loss (SNHL)
• Improvement of Quality of Life by Cannabinoids in Oncologic Patients (BELCANTO) Ended
  2024-518917-24-00 4 2023-11-08 oncology, palliative care, quality of life
• A trial to evaluate the efficacy and safety of different doses of LEO 138559 in adults with moderate-to-severe atopic dermatitis. Ended
  2022-500777-14-00 4 2023-11-06 Atopic Dermatitis
• Efficacy and Tolerability of AP707 in Patients with chronic Pain due to Diabetic Polyneuropathy Ended
  2022-500897-32-00 5 2023-11-02 Chronic pain due to diabetic polyneuropathy
• Efficacy and Tolerability of AP707 in Patients with chronic Pain due to traumatic or post-operative peripheral Neuropathy Ended
  2022-500898-13-00 5 2023-11-02 Chronic Pain due to traumatic or post-operative peripheral Neuropathy
• Efficacy and Tolerability of AP707 in Patients with chronic pain due to central Neuropathy of any Genesis Ended
  2022-500899-66-00 5 2023-11-02 Chronic pain due to central Neuropathy of any Genesis
• Efficacy and Tolerability of AP707 in Patients with Chronic Back Pain Ended
  2022-502151-54-00 5 2023-11-02 Chronic back pain

Showing 337–360 of 426 trials